#Taiwan #Taipei #Parkinson's Disease #Energenesis Biomedical #ENERGI-F705PD

Energenesis Biomedical to Unveil Parkinson's Disease Therapy at BIO International 2025

Energenesis Biomedical Co., Ltd., a pioneering clinical-stage biotechnology firm, is poised to showcase its progress on ENERGI-F705PD at the upcoming BIO International Convention 2025. This prominent event will take place from June 16 to 19 in Boston, MA, at Booth #1645 within the Taiwan Pavilion. The company is eager to present its innovative ENERGI Platform, specifically highlighting the investigational therapy ENERGI-F705PD, which stands out as a first-in-class treatment with the potential to modify the course of Parkinson's disease (PD).

Key Features of ENERGI-F705PD

Disease-Modifying Potential

ENERGI-F705PD is not just another treatment; it is designed as an oral sustained-release therapy aimed at tackling the complex pathogenesis underlying Parkinson's disease. By focusing on the root causes of the illness, this therapy holds promise for significantly improving patients' lives.

Upcoming Trial Results

The company anticipates releasing topline data from its Phase I clinical trial involving healthy volunteers in September 2025. This development follows a successful recruitment phase, and the results are expected to provide insights into the therapy’s safety and efficacy.

Mechanism of Action

The centerpiece of ENERGI-F705PD's promise lies in its multi-faceted approach:

• - Reducing Alpha-Synuclein Aggregation: By preventing the aggregation of misfolded alpha-synuclein—an essential factor in the pathology of PD—the therapy aims to intervene early in the disease process.
• - Enhancing Antioxidant Production: The drug stimulates the pentose phosphate pathway, thus increasing NADPH production which plays a crucial role in strengthening the cell's defense against oxidative damage.
• - Boosting Dopamine Synthesis: By optimizing cellular energy and supporting the essential enzyme tyrosine hydroxylase, ENERGI-F705PD helps restore dopamine levels in the brain, addressing one of the primary neurological deficits experienced by PD patients.

Insights from the CEO

Dr. Han-Min Chen, CEO of Energenesis Biomedical, expressed enthusiasm about presenting the advancements of the ENERGI-F705PD program at this key event. Emphasizing the unmet needs that remain in dealing with Parkinson's disease, he highlighted the innovative approach taken by the company to restore cellular energy as central to the development of a potential disease-modifying solution. He stated, "Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients."

Company Background

Founded with a mission to innovate within the biopharmaceutical industry, Energenesis Biomedical Co., Ltd. specializes in developing therapies that revitalize cellular energy and activate intrinsic repair mechanisms. The company leverages proprietary small-molecule innovations alongside AI-driven drug repurposing strategies to expedite the development of treatments catering to various unmet medical needs.

Pipeline Overview

Energenesis' diverse pipeline includes:

• - ENERGI-F705PD: An oral tablet for Parkinson's disease (currently in Phase I).
• - ENERGI-F703DFU: A gel for treating diabetic foot ulcers (in Phase III).
• - ENERGI-F701: A tonic for alopecia (Phase II completed).
• - ENERGI-F703EB: A cream for epidermolysis bullosa (EB), which has received FDA orphan drug and EMA orphan designation and is preparing for Phase II trials.

If you're interested in learning more about this cutting-edge research or the company’s initiatives, visit www.energenesis-biomedical.com/en.